Nor surprising, Gene Therapy is on the nose across all indications - FDA met with Big Pharma a few months back to discuss safety issues.
Pfizer, Sarepta - and Roche's investment in Sarepta's GT - won't see commercialization anytime soon.
First we had Sarepta's "unlucky randomization" excuse in January, now we Pfizer excluding segments of DMD population.
A set back for the DMD community for sure....BUT...a great opportunity for ANP to add a few hundred mill to their partnership agreement..
.
Where others have failed will Atl1102 succeed ?, page-388
-
- There are more pages in this discussion • 709 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
